Susana Ortiz-Urda, MD, PhD

Title(s)Associate Professor, Dermatology
SchoolSchool of Medicine
Address2340 Sutter Street, #N419
San Francisco CA 94115
Phone415-476-8502
PronounsShe/Her/Hers
ORCID ORCID Icon0000-0002-5979-8876 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of ViennaM.D.1998School of Medicine
    Rappersberger, University of ViennaPhD1998Biology
    University of ViennaResearch Fellow1999Dermatology
    AKH ViennaResearch Resident2001Dermatology
    Stanford UniversityPostdoctoral Fellowship2005Epithelial Biology
    The Brooklyn Hospital Center, NYInternship2006Medicine
    Stanford UniversityResident2010Dermatology
    University of California, San Francisco Research Fellowship 2010Derm-Oncology
    New York University, NYM.B.A.2014Business Administration

    Collapse Overview 
    Collapse Overview
    Dr. Susana Ortiz-Urda is a dermatologist and melanoma specialist who serves as co-director of the UCSF Melanoma Center. She cares for patients with early and advanced melanoma.

    Ortiz-Urda’s lab works with human models of epithelial neoplasia and melanoma. She studies cancer signaling at a genetic sequencing level to identify novel transcripts, their functions and the factors that promote resistance to drugs or cancer progression. She hopes her findings may point to key biomarkers or new targets for treating melanoma.

    Ortiz-Urda earned her medical degree and doctorate at the University of Vienna. She completed a residency in dermatology and a postdoctoral fellowship in epithelial biology at Stanford University, followed by a cutaneous oncology fellowship at UCSF. She earned her master of business administration degree at New York University.

    Ortiz-Urda is a member of the American Academy of Dermatology, Austrian Society of Dermatology and Venereology, and Dermatology Foundation. She has received several honors, including the Kardinal-Innitzer Award for Outstanding Science in Dermatology and the Unilever Award from the Austrian Society of Dermatology and Venereology.

    Learn more about Ortiz-Urda's research: http://cancer.ucsf.edu/research/ortiz-lab.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Poor melanoma outcomes and survival in Asian American and Pacific Islander patients. J Am Acad Dermatol. 2021 Jun; 84(6):1725-1727. Zheng YJ, Ho C, Lazar A, Ortiz-Urda S. PMID: 32860918.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    2. A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma. Pigment Cell Melanoma Res. 2019 07; 32(4):603-606. Algazi AP, Rotow J, Posch C, Ortiz-Urda S, Pelayo A, Munster PN, Daud A. PMID: 30801911.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    3. MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and 'wild type' melanomas. Oncotarget. 2018 Oct 09; 9(79):34990-34995. Posch C, Sanlorenzo M, Ma J, Kim ST, Zekhtser M, Ortiz-Urda S. PMID: 30405888; PMCID: PMC6201855.
      View in: PubMed   Mentions: 7     Fields:    
    4. The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma. Sci Rep. 2018 Jul 19; 8(1):10902. Sanlorenzo M, Vujic I, Esteve-Puig R, Lai K, Vujic M, Lin K, Posch C, Dimon M, Moy A, Zekhtser M, Johnston K, Gho D, Ho W, Gajjala A, Oses Prieto J, Burlingame A, Daud A, Rappersberger K, Ortiz-Urda S. PMID: 30026510; PMCID: PMC6053443.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    5. Cutaneous CD56+ T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma. JAAD Case Rep. 2018 Jul; 4(6):540-542. Zheng YJ, Lee A, Pincus L, Ho W, Vujic M, Ortiz-Urda S. PMID: 29892669; PMCID: PMC5991899.
      View in: PubMed   Mentions: 10  
    6. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. Pigment Cell Melanoma Res. 2018 01; 31(1):110-114. Algazi AP, Esteve-Puig R, Nosrati A, Hinds B, Hobbs-Muthukumar A, Nandoskar P, Ortiz-Urda S, Chapman PB, Daud A. PMID: 28921907; PMCID: PMC8049535.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    7. New insights in melanoma biomarkers: long-noncoding RNAs. Melanoma Manag. 2016 Sep; 3(3):195-205. Moreno-Traspas R, Vujic I, Sanlorenzo M, Ortiz-Urda S. PMID: 30190889; PMCID: PMC6094599.
      View in: PubMed   Mentions:
    8. Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo. Oncotarget. 2016 Jul 19; 7(29):45916-45925. Posch C, Moslehi H, Sanlorenzo M, Green G, Vujic I, Panzer-Grümayer R, Rappersberger K, Ortiz-Urda S. PMID: 27322141; PMCID: PMC5216770.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    9. Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells. J Invest Dermatol. 2016 10; 136(10):2041-2048. Posch C, Sanlorenzo M, Vujic I, Oses-Prieto JA, Cholewa BD, Kim ST, Ma J, Lai K, Zekhtser M, Esteve-Puig R, Green G, Chand S, Burlingame AL, Panzer-Grümayer R, Rappersberger K, Ortiz-Urda S. PMID: 27251789; PMCID: PMC6373467.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    10. Oncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome. J Proteomics. 2016 07 20; 144:140-7. Sanlorenzo M, Vujic I, Posch C, Ma J, Lin K, Lai K, Lee D, Vujic M, Oses-Prieto JA, Chand S, Rodriguez-Peralto JL, Burlingame A, Ortiz-Urda S. PMID: 27216642; PMCID: PMC5026456.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    11. Searching for the Chokehold of NRAS Mutant Melanoma. J Invest Dermatol. 2016 07; 136(7):1330-1336. Posch C, Vujic I, Monshi B, Sanlorenzo M, Weihsengruber F, Rappersberger K, Ortiz-Urda S. PMID: 27160069; PMCID: PMC4921268.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    12. Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. Oncotarget. 2016 Feb 09; 7(6):7297-306. Vujic I, Sanlorenzo M, Esteve-Puig R, Vujic M, Kwong A, Tsumura A, Murphy R, Moy A, Posch C, Monshi B, Rappersberger K, Ortiz-Urda S. PMID: 26771141; PMCID: PMC4872786.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    13. The burden of malignant melanoma--lessons to be learned from Austria. Eur J Cancer. 2016 Mar; 56:45-53. Monshi B, Vujic M, Kivaranovic D, Sesti A, Oberaigner W, Vujic I, Ortiz-Urda S, Posch C, Feichtinger H, Hackl M, Rappersberger K. PMID: 26802530.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    14. Time-Dependent Measurement of Adverse Events-Reply. JAMA Dermatol. 2015 Dec 01; 151(12):1392-1393. Sanlorenzo M, Vujic I, Ortiz-Urda S. PMID: 26650664; PMCID: PMC11037295.
      View in: PubMed   Mentions:    Fields:    
    15. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol. 2015 Nov; 151(11):1206-1212. Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S. PMID: 26222619; PMCID: PMC5061067.
      View in: PubMed   Mentions: 189     Fields:    Translation:Humans
    16. Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox. Clin Cosmet Investig Dermatol. 2015; 8:423-9. Goldenberg A, Vujic I, Sanlorenzo M, Ortiz-Urda S. PMID: 26346576; PMCID: PMC4531028.
      View in: PubMed   Mentions: 6  
    17. Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma. J Invest Dermatol. 2015 Oct; 135(10):2475-2483. Posch C, Cholewa BD, Vujic I, Sanlorenzo M, Ma J, Kim ST, Kleffel S, Schatton T, Rappersberger K, Gutteridge R, Ahmad N, Ortiz/Urda S. PMID: 26016894; PMCID: PMC4567913.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    18. Correction: Cost-Effectiveness Of Treatment Strategies for BRAF-Mutated Metastatic Melanoma. PLoS One. 2015; 10(4):e0126988. Curl P, Vujic I, van 't Veer LJ, Ortiz-Urda S, Kahn JG. PMID: 25893993; PMCID: PMC4404367.
      View in: PubMed   Mentions:    Fields:    
    19. The risk of melanoma in pilots and cabin crew: UV measurements in flying airplanes. JAMA Dermatol. 2015 Apr; 151(4):450-2. Sanlorenzo M, Vujic I, Posch C, Cleaver JE, Quaglino P, Ortiz-Urda S. PMID: 25517516; PMCID: PMC4476387.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    20. The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. Br J Cancer. 2015 Apr 14; 112(8):1326-31. Algazi AP, Cha E, Ortiz-Urda SM, McCalmont T, Bastian BC, Hwang J, Pampaloni MH, Behr S, Chong K, Cortez B, Quiroz A, Coakley F, Liu S, Daud AI. PMID: 25867272; PMCID: PMC4402449.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    21. Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticles. Biomed Microdevices. 2015 Feb; 17(1):15. Posch C, Latorre A, Crosby MB, Celli A, Latorre A, Vujic I, Sanlorenzo M, Green GA, Weier J, Zekhtser M, Ma J, Monico G, Char DH, Jusufbegovic D, Rappersberger K, Somoza Á, Ortiz-Urda S. PMID: 25653058; PMCID: PMC4586106.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    22. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget. 2015 Jan 20; 6(2):969-78. Vujic I, Sanlorenzo M, Posch C, Esteve-Puig R, Yen AJ, Kwong A, Tsumura A, Murphy R, Rappersberger K, Ortiz-Urda S. PMID: 25504439; PMCID: PMC4359268.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimalsCells
    23. The risk of melanoma in airline pilots and cabin crew: a meta-analysis. JAMA Dermatol. 2015 Jan; 151(1):51-8. Sanlorenzo M, Wehner MR, Linos E, Kornak J, Kainz W, Posch C, Vujic I, Johnston K, Gho D, Monico G, McGrath JT, Osella-Abate S, Quaglino P, Cleaver JE, Ortiz-Urda S. PMID: 25188246; PMCID: PMC4482339.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansPHPublic Health
    24. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014 Dec; 71(6):1102-1109.e1. Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S. PMID: 25440439; PMCID: PMC4254519.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    25. Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies. Oncotarget. 2014 Sep 15; 5(17):7936-44. Vujic I, Posch C, Sanlorenzo M, Yen AJ, Tsumura A, Kwong A, Feichtenschlager V, Lai K, Arneson DV, Rappersberger K, Ortiz-Urda SM. PMID: 25277205; PMCID: PMC4202171.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    26. Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma. PLoS One. 2014; 9(9):e107255. Curl P, Vujic I, van 't Veer LJ, Ortiz-Urda S, Kahn JG. PMID: 25198196; PMCID: PMC4157865.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    27. Merkel cell carcinoma: mitoses, expression of Ki-67 and bcl-2 correlate with disease progression. J Eur Acad Dermatol Venereol. 2015 Mar; 29(3):542-8. Vujic I, Marker M, Posch C, Mühlehner D, Monshi B, Breier F, Steiner A, Ortiz-Urda S, Rappersberger K. PMID: 25088273.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    28. DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics. Nanoscale. 2014 Jul 07; 6(13):7436-42. Latorre A, Posch C, Garcimartín Y, Celli A, Sanlorenzo M, Vujic I, Ma J, Zekhtser M, Rappersberger K, Ortiz-Urda S, Somoza Á. PMID: 24882040.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    29. Single-point mutation detection in RNA extracts using gold nanoparticles modified with hydrophobic molecular beacon-like structures. Chem Commun (Camb). 2014 Mar 21; 50(23):3018-20. Latorre A, Posch C, Garcimartín Y, Ortiz-Urda S, Somoza Á. PMID: 24496380; PMCID: PMC4339280.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    30. Melanoma immunotherapy. Cancer Biol Ther. 2014 Jun 01; 15(6):665-74. Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A, Osella-Abate S, Quaglino P, Daud A, Ortiz-Urda S. PMID: 24651672; PMCID: PMC4049781.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    31. Mycoplasma pneumoniae-associated mucositis--case report and systematic review of literature. J Eur Acad Dermatol Venereol. 2015 Mar; 29(3):595-8. Vujic I, Shroff A, Grzelka M, Posch C, Monshi B, Sanlorenzo M, Ortiz-Urda S, Rappersberger K. PMID: 24665876.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    32. Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. Br J Cancer. 2014 Mar 18; 110(6):1427-32. Posch C, Weihsengruber F, Bartsch K, Feichtenschlager V, Sanlorenzo M, Vujic I, Monshi B, Ortiz-Urda S, Rappersberger K. PMID: 24518593; PMCID: PMC3960625.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    33. NRAS mutant melanoma--undrugable? Oncotarget. 2013 Apr; 4(4):494-5. Posch C, Ortiz-Urda S. PMID: 23660168; PMCID: PMC3720596.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    34. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A. 2013 Mar 05; 110(10):4015-20. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S. PMID: 23431193; PMCID: PMC3593920.
      View in: PubMed   Mentions: 126     Fields:    Translation:HumansAnimalsCells
    35. Cutting edge in medical management of cutaneous oncology. Semin Cutan Med Surg. 2012 Jun; 31(2):140-9. Chong K, Daud A, Ortiz-Urda S, Arron ST, UCSF High Risk Skin Cancer Program. PMID: 22640435; PMCID: PMC3367308.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    36. Modeling inducible human tissue neoplasia identifies an extracellular matrix interaction network involved in cancer progression. Cancer Cell. 2009 Jun 02; 15(6):477-88. Reuter JA, Ortiz-Urda S, Kretz M, Garcia J, Scholl FA, Pasmooij AM, Cassarino D, Chang HY, Khavari PA. PMID: 19477427; PMCID: PMC3050547.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansAnimalsCells
    37. A laminin-collagen complex drives human epidermal carcinogenesis through phosphoinositol-3-kinase activation. Cancer Res. 2007 May 01; 67(9):4264-70. Waterman EA, Sakai N, Nguyen NT, Horst BA, Veitch DP, Dey CN, Ortiz-Urda S, Khavari PA, Marinkovich MP. PMID: 17483338.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    38. Type VII collagen is required for Ras-driven human epidermal tumorigenesis. Science. 2005 Mar 18; 307(5716):1773-6. Ortiz-Urda S, Garcia J, Green CL, Chen L, Lin Q, Veitch DP, Sakai LY, Lee H, Marinkovich MP, Khavari PA. PMID: 15774758.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    39. [Erythema induratum-nodular vasculitis]. J Dtsch Dermatol Ges. 2004 Mar; 2(3):206-14; quiz 215. Marker M, Ortiz-Urda S, Lilgenau N, Rappersberger K. PMID: 16281639.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    40. Carbamazepine-induced DRESS syndrome with recurrent fever and exanthema. Int J Dermatol. 2004 Jan; 43(1):51-4. Valencak J, Ortiz-Urda S, Heere-Ress E, Kunstfeld R, Base W. PMID: 14693022.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    41. The plant lectin wheat germ agglutinin inhibits the binding of pemphigus foliaceus autoantibodies to desmoglein 1 in a majority of patients and prevents pathomechanisms of pemphigus foliaceus in vitro and in vivo. J Immunol. 2003 Dec 01; 171(11):6244-50. Ortiz-Urda S, Elbe-Bürger A, Smolle J, Marquart Y, Chudnovsky Y, Ridky TW, Bernstein P, Wolff K, Rappersberger K. PMID: 14634141.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    42. Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. Gene Ther. 2003 Jul; 10(13):1099-104. Ortiz-Urda S, Lin Q, Yant SR, Keene D, Kay MA, Khavari PA. PMID: 12808440.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    43. PhiC31 integrase-mediated nonviral genetic correction of junctional epidermolysis bullosa. Hum Gene Ther. 2003 Jun 10; 14(9):923-8. Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Calos MP, Khavari PA. PMID: 12828862.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    44. [New immunosuppressive agents for treating psoriasis]. Hautarzt. 2003 Mar; 54(3):230-6. Ortiz-Urda S, Rappersberger K. PMID: 12634991.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    45. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest. 2003 Jan; 111(2):251-5. Ortiz-Urda S, Lin Q, Green CL, Keene DR, Marinkovich MP, Khavari PA. PMID: 12531881; PMCID: PMC151880.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimalsCells
    46. Stable nonviral genetic correction of inherited human skin disease. Nat Med. 2002 Oct; 8(10):1166-70. Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Fang M, Calos MP, Khavari PA. PMID: 12244305.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansAnimalsCells
    47. Pathogenesis of the permeability barrier abnormality in epidermolytic hyperkeratosis. J Invest Dermatol. 2001 Oct; 117(4):837-47. Schmuth M, Yosipovitch G, Williams ML, Weber F, Hintner H, Ortiz-Urda S, Rappersberger K, Crumrine D, Feingold KR, Elias PM. PMID: 11676820.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    48. A localized variant of paraneoplastic pemphigus: acantholysis associated with malignant melanoma. Br J Dermatol. 2001 Jun; 144(6):1249-54. Schaeppi H, Bauer JW, Hametner R, Metze D, Ortiz-Urda S, Salmhofer W, Rappersberger K, Hintner H. PMID: 11422052.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    Susana's Networks
    Concepts (282)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (22)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.